ライフサイエンスコーパス: pleurodesis

1 eving control of malignant pleural effusion (pleurodesis).

2 for chest tube insertion and talc for slurry pleurodesis.

3 ave a role in symptom control beyond that of pleurodesis.

4 ue diagnosis or to effect symptom control by pleurodesis.

5 tly (P =.044) more negative in patients with pleurodesis.

6 ower morbidity than do those who do not have pleurodesis.

7 nt small-bore-catheter thoracostomy and talc pleurodesis.

8 desis would influence the development of the pleurodesis.

9 n molecules that may play a critical role in pleurodesis.

10 ant candidates should minimize the extent of pleurodesis.

11 6 patients, of whom 175 (88 assigned to talc pleurodesis, 87 assigned to VAT-PP) had confirmed mesoth

12 ade conditional recommendations for offering pleurodesis after an initial pneumothorax rather than po

13 pared with the toxicity profiles of standard pleurodesis agents.

14 urodesis (on a scale of 0 to 4, where 0 = no pleurodesis and 4 = complete pleurodesis) with mean scor

15 ich valves, digital air-leak monitoring, and pleurodesis at first presentation might lead to an incre

16 significant difference between IPCs and talc pleurodesis at relieving patient-reported dyspnea.

17 edure until the first recurrence and against pleurodesis being used as a reason to exclude patients f

18 und in LOS, CTO5, CTO10, CTO20, and need for pleurodesis between patients in RV/LV, FO/FC, IF/EF, or

19 eural injection of TGF-beta(2) may produce a pleurodesis both safely and painlessly.

20 omly assigned (1:1) to either VAT-PP or talc pleurodesis by computer-generated random numbers, strati

21 [VAS] 4 times/d; superiority comparison) and pleurodesis efficacy at 3 months (failure defined as nee

22 NSAID use resulted in noninferior rates of pleurodesis efficacy at 3 months.

23 There is early evidence of LTA-T-induced pleurodesis efficacy, suggesting that this might be a vi

24 t failed to meet noninferiority criteria for pleurodesis efficacy.

25 (NSAIDs) are avoided because they may reduce pleurodesis efficacy.

26 24F chest tubes were associated with higher pleurodesis failure (30% vs 24%), failing to meet noninf

27 Pleurodesis failure occurred in 30 patients (20%) in the

28 of TGF-beta2 would (1) produce an effective pleurodesis faster; (2) stimulate more collagen depositi

29 tion to the talc, and essentially prevents a pleurodesis from developing.

30 the VAT-PP group and 57% (46-66) in the talc pleurodesis group (hazard ratio 1.04 [95% CI 0.76-1.42];

31 Pleurodesis had no statistically significant effect on t

32 s painful than larger tubes, but efficacy in pleurodesis has not been proven.

33 ents with mesothelioma who have talc-induced pleurodesis have a lower morbidity than do those who do

34 clinical trial among 320 patients requiring pleurodesis in 16 UK hospitals from 2007 to 2013.

35 ntrapleural injection of TGF-beta(2) induces pleurodesis in a dose-dependent manner.

36 A dose of 5.0 microg produced satisfactory pleurodesis in almost all of the rabbits so treated.

37 erall survival, and cost, of VAT-PP and talc pleurodesis in patients with malignant pleural mesotheli

38 The ability of TGF-beta to produce a pleurodesis in patients with recurrent pleural effusions

39 ministration of TGF-beta2 produced excellent pleurodesis in rabbits at a rate faster than talc slurry

40 has recently been shown to produce effective pleurodesis in rabbits.

41 factor beta(2) (TGF-beta(2)) would produce a pleurodesis in rabbits.

42 Pleurodesis influences the relationship between CT measu

43 Pleural abrasion with minocycline pleurodesis is as effective as apical pleurectomy and ei

44 5, CTO10, and CTO20, respectively), need for pleurodesis, length of hospital stay (LOS), operation du

45 f corticosteroids at the time of talc-slurry pleurodesis markedly decreases the inflammatory reaction

46 to malignant pleural mesothelioma, and talc pleurodesis might be preferable considering the fewer co

47 tly more common after VAT-PP than after talc pleurodesis, occurring in 24 (31%) of 78 patients who co

48 ulmonary function tests and the influence of pleurodesis on these findings were assessed with regress

49 of TGF-beta(2) resulted in a dose-dependent pleurodesis (on a scale of 0 to 4, where 0 = no pleurode

50 is, follow up after thoracentesis, and offer pleurodesis or a drainage procedure for patients with re

51 ith 3 days (2-5) for those who received talc pleurodesis (p<0.0001).

52 ged LOS, greater chest tube output, and more pleurodesis (P<0.05), and PAP was related to CTO5 and CT

53 ten (14%) of 73 patients who completed talc pleurodesis (p=0.019), as were respiratory complications

54 ivariate analysis, performance of a chemical pleurodesis procedure and prolonged cardiopulmonary bypa

55 The optimal thoracoscopic pleurodesis procedure for PSP with high recurrence risk

56 and show a four-fold increase when a similar pleurodesis procedure is done with a video-assisted appr

57 the risk of infection, and may necessitate a pleurodesis procedure.

58 ced effective pleurodesis within 7 d (median pleurodesis score = 7 at Day 7).

59 all 10 rabbits that received talc only had a pleurodesis score of 3 or 4, whereas only four of the 10

60 10 rabbits that also received steroids had a pleurodesis score of 3 or 4.

61 h malignant pleural effusion and no previous pleurodesis, there was no significant difference between

62 In studies that did the same pleurodesis through two different forms of access, the r

63 Thirty-seven patients with LAM (17 with pleurodesis) underwent CT and pulmonary function tests.

64 Gross pleurodesis was graded from 1 (none) to 8 (complete symp

65 Small-bore-catheter thoracostomy and talc pleurodesis was successful in treating malignant pleural

66 ing growth factor beta (TGF-beta) to produce pleurodesis, we observed that although TGF-beta was more

67 tive protein from baseline to 48 hours after pleurodesis were recorded.

68 al effusion who had not previously undergone pleurodesis were recruited from 143 patients who were tr

69 We report two trials describing whether talc pleurodesis with a mean particle size of less than 15 mi

70 Pleurodesis with talc is an accepted method for the trea

71 4, where 0 = no pleurodesis and 4 = complete pleurodesis) with mean scores of 3.6, 2.6, 1.5, 0.7, and

72 al injection of TGF-beta2 produced effective pleurodesis within 7 d (median pleurodesis score = 7 at

73 t use of steroids at the time of talc-slurry pleurodesis would influence the development of the pleur

74 lude that the routine use of graded talc for pleurodesis would reduce the morbidity of this procedure